Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,446 total articles
Ernexa Therapeutics announced key progress in developing its lead cell therapy candidate, ERNA-101, reaching critical manufacturing and process development milestones to support an Investigational New Drug (IND) submission targeted for Q3 2026. The company has moved into GMP manufacturing and ongoing technology transfer to prepare for the first-in-…
RenX Enterprises Corp. announced that its subsidiary Zimmer Equipment Inc. has been approved as a master carrier for one of the largest U.S. steel manufacturers, allowing it to transport steel products across multiple facilities in the country. This new commercial relationship enhances ZEI's logistics operations, providing recurring freight busines…
Genius Group Limited (NYSE American: GNS) announced its Board approval of a new AI Treasury strategy, launching the AGI Infinity Portfolio with an initial investment target of $100 million focused on artificial general intelligence and frontier AI companies such as SpaceX, OpenAI, and Anthropic. The five-year plan aims to grow the AI Treasury porti…
Trident Digital Tech Holdings Ltd., a Singapore-based technology holding company listed on Nasdaq, announced its regaining of full compliance with Nasdaq's minimum bid price rule, leading to the cancellation of a previously scheduled Nasdaq hearing. This resolution enables the company to maintain its Nasdaq listing, supporting its strategic transfo…
Ingredion Incorporated announced a significant milestone with over 96% of its tier 1 priority crops now sourced sustainably, up from 25% five years ago. This progress reflects the company's integrated approach to sustainability across its operations and partnerships. Additional highlights include high waste diversion rates, strengthened human right…
Amarin Corporation presented new data at the EAS Congress 2026, demonstrating that risk-weighted apolipoprotein B (RW-apoB) more effectively identifies residual cardiovascular risk in statin-treated patients with elevated triglycerides than traditional lipid markers. This insight builds on the REDUCE-IT trial results, supporting the clinical releva…
CDT Equity Inc. announced that the patent for AZD5904 in treating male infertility has been granted in Canada, completing patent approvals in all major pharmaceutical markets. This strengthens the company's intellectual property portfolio for AZD5904, a drug originally licensed from AstraZeneca, addressing a significant unmet need in the $4.4 billi…
Hemab Therapeutics, a clinical-stage biotechnology company focused on innovative therapies for blood coagulation disorders, announced its participation in the 2026 Jefferies Global Healthcare Conference with a fireside chat and investor meetings. The company is advancing its pipeline, including bispecific and monovalent antibodies targeting rare co…
Brag House Holdings, in partnership with House of Doge and the Dogecoin Foundation, launched the beta version of Such, a direct-to-consumer mobile app integrating Dogecoin blockchain features to facilitate real-world commerce with DOGE. The app offers a multi-functional self-custodial wallet, a commerce engine for goods and service payments in Doge…
Madrigal Pharmaceuticals presented data from its Phase 3 MAESTRO program and real-world studies demonstrating that its drug Rezdiffra (resmetirom) significantly reduces cardiovascular risk markers and improves liver health in patients with metabolic dysfunction-associated steatohepatitis (MASH). The data show reductions in LDL-C, ApoB, Lp(a), and i…
Enlivex Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, highlights the Rain Protocol's $100 million liquidity injection, placing Rain among the top three global prediction market platforms by total value locked. Enlivex holds substantial RAIN tokens and an option to acquire more, underpinning confidence in its dual strategy combining l…
Altimmune, Inc. announced new analyses from its IMPACT Phase 2b trial showing pemvidutide, a novel glucagon/GLP-1 dual receptor agonist, significantly improves multiple non-invasive markers of metabolic dysfunction-associated steatohepatitis (MASH) activity and fibrosis after 24 weeks of treatment. AI-based digital pathology further confirmed antif…
4D Molecular Therapeutics announced participation in upcoming June investor conferences, where company management will present and hold one-on-one meetings. The biotech firm is advancing late-stage gene therapy candidates targeting serious conditions such as wet age-related macular degeneration and cystic fibrosis, with multiple programs in clinica…
Here Group Limited, a company specializing in IP-based collectible pop toys, will release its unaudited financial results for the third fiscal quarter ended March 31, 2026, before the US market opens on June 5, 2026. Management will hold an earnings call to discuss the results, providing insights into the company's performance and outlook.
Sionna Therapeutics announced management's participation in two key upcoming investor conferences in June 2026 to present updates on its clinical-stage pipeline focused on developing novel CFTR modulators for cystic fibrosis treatment. The company aims to advance medicines targeting the F508del mutation by stabilizing CFTR's NBD1, with hopes to sig…
Opus Genetics, a clinical-stage biopharmaceutical company focused on developing gene therapies to restore vision for inherited retinal diseases, announced it will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company's pipeline includes seven AAV-based gene therapy programs targeting various genetic retinal disorde…
Collegium Pharmaceutical announced that its management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The event, scheduled for June 3, 2026, will include a live webcast available on the company’s website. Collegium is a biopharmaceutical company specializing in treatments for central nervous system and …
Galectin Therapeutics presented new analyses from the NAVIGATE trial at the EASL 2026 Congress, showing that belapectin significantly reduces varices development and improves markers of fibrosis and portal hypertension risk in patients with advanced MASH cirrhosis. The data support belapectin's role as a disease-modifying therapy targeting fibrotic…
Live Oak Bank has committed $1 million over five years to The Forward Fund, a North Carolina-based pay-it-forward financing program. The initiative provides zero-percent interest loans to working adults for career training in high-demand fields, fostering workforce upskilling and economic mobility. In its first year, the program issued $2.3 million…
Mesa Laboratories, Inc. announced its fiscal year 2026 financial results, reporting 3.4% revenue growth driven primarily by its Sterilization and Disinfection Control division, offset by declines in Biopharmaceutical Development due to export controls and commercial execution challenges. Operating income rose 13.3%, aided by cost realignment and ba…
Freshworks Inc. releases a report detailing how mid-market companies lose on average 25% of their AI budgets to complexity overhead before achieving returns, with increased workload and integration challenges delaying ROI realization. Despite these hurdles, most mid-market organizations plan to increase AI investments, focusing on AI solutions that…
Annexon, Inc., a biopharmaceutical company focused on targeted immunotherapies for neuroinflammatory diseases, announced that CEO Douglas Love will participate in investor conferences in June 2026 to discuss company progress and strategy. Live webcasts of presentations will be available online.
Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on inhaled therapies for serious respiratory diseases, announced that its management will present an overview of the company at the Jefferies Global Healthcare Conference. The presentation will cover Avalyn's development of inhaled formulations of antifibrotic drugs targeting pu…
Pacira BioSciences reports real-world study findings showing that use of EXPAREL, their non-opioid pain therapy, in outpatient total shoulder arthroplasty patients led to reduced opioid use, fewer opioid-related adverse events, and lower healthcare costs compared to standard analgesia. These findings support the expanding role of non-opioid pain ma…
Mission Produce, Inc., a leading global supplier of fresh Hass avocados and other produce, will release its fiscal second quarter 2026 financial results after market close on June 8, 2026. The company will also hold a conference call and webcast to discuss the results.
